Opdivo-Yervoy Combination Demonstrates Two-Year Survival Rate of 69 Percent

Remote telemedicine tool found highly accurate in diagnosing melanoma

Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.

November 22, 2024

Vol.50 No.44

Clinical Roundup

UVA Health tests focused ultrasound to increase immune response in melanoma

A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

FDA approved an Investigational Device Exemption application to initiate a multi-center study for the treatment of recurrent cutaneous squamous cell carcinoma in immunocompromised patients using the Alpha DaRT.

October 11, 2024

Vol.50 No.38

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.

September 27, 2024

Vol.50 No.36

Regulatory News

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Follow-up data from the phase IIb randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with Keytruda in patients with resected high-risk melanoma (stage 3/4) following complete resection.

September 20, 2024

Vol.50 No.35

Opdivo-Yervoy Combination Demonstrates Two-Year Survival Rate of 69 Percent

YOU MAY BE INTERESTED IN

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Renew today!

Subscriber content

Never miss an issue!

Login

Opdivo-Yervoy Combination Demonstrates Two-Year Survival Rate of 69 Percent

YOU MAY BE INTERESTED IN

Remote telemedicine tool found highly accurate in diagnosing melanoma

UVA Health tests focused ultrasound to increase immune response in melanoma

FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation

Adjuvant treatment with cancer vaccine + Keytruda shows continued improvement in RFS and DMFS in resected high-risk advanced melanoma

Never miss an issue!

Login

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation